$6.62
-2.4%BlackRock Innovation and Growth Trust (the Trust) is a newly-organized, non-diversified, closed-end management investment company with no operating history. The Trusts investment objectives are to provide total return and income through a combination of current income, current gains and long-term capital appreciation. There can be no assurance that the Trusts investment objectives will be achieved or that the Trusts investment program will be successful The Trust will invest primarily in equity securities issued by mid- and small-capitalization companies that the Trusts adviser believes have above-average earnings growth potential. In selecting investments for the Trust, the Trusts adviser focuses on mid- and small-capitalization growth companies that are innovative. These are companies that have introduced, or are seeking to introduce, a new product or service that potentially changes the marketplace.
Last Annual Value
1.81B
3-Year CAGR
-23%
5-Year CAGR
-15%
10-Year CAGR
-8%
| Company | Total Liabilities and Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
1.81B | -4.4% | -14.8% | N/A | ||
![]() Savara Inc. NASDAQ:SVRA | 253.44M | 12.6% | 7.5% | 24.2% | |
![]() Tyra Biosciences, Inc. NASDAQ:TYRA | 282.61M | 7.8% | -1.6% | N/A | |
![]() Maravai LifeSciences Holdings, Inc. NASDAQ:MRVI | 770.58M | -19.7% | -16.7% | N/A | |
![]() CorMedix Inc. NASDAQ:CRMD | 826.14M | 115.9% | 64.3% | 43.8% | |
![]() Rezolute, Inc. NASDAQ:RZLT | 175.49M | 12.4% | 32.7% | 32.0% | |
![]() Kura Oncology, Inc. NASDAQ:KURA | 738.36M | 18.0% | 6.7% | 26.6% | |
![]() Theravance Biopharma, Inc. NASDAQ:TBPH | 485.57M | 8.3% | 5.3% | -2.7% | |
![]() Prime Medicine, Inc. NASDAQ:PRME | 342.73M | 20.9% | 2.6% | N/A | |
![]() LENZ Therapeutics, Inc. NASDAQ:LENZ | 305.88M | 63.2% | 75.6% | N/A |
Continue your BTX research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.